US2020268670A1PendingUtilityA1

Trans-Catheter Local Immunotherapy for Solid Tumors

50
Assignee: ENDOBAR SOLUTIONS LLCPriority: Feb 22, 2019Filed: Feb 21, 2020Published: Aug 27, 2020
Est. expiryFeb 22, 2039(~12.6 yrs left)· nominal 20-yr term from priority
Inventors:Nicholas KipshidzeZurab Kakabadze
A61K 40/42A61K 40/31A61K 40/11A61K 9/1676A61K 9/0019A61M 2025/1052A61M 25/10A61K 35/17
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Tumors can be treated by introducing a first embolization agent (e.g., small embolic beads) into a blood vessel that supplies blood to the tumor, then introducing a therapeutic substance into the blood vessel at a position that is proximal with respect to the first embolization agent, and then introducing a second embolization agent (e.g., large embolic beads) into the blood vessel at a position that is proximal with respect to at least a portion of the therapeutic substance. The first embolization agent prevents complete systemic release of the substance, and the second embolization agent prevents retrograde washout of the substance. In some embodiments, the first embolization agent is omitted, and the second embolization agent impedes systemic release by impeding the forward flow of blood. In some embodiments, the therapeutic substance is an immunotherapy substance (e.g., CAR T-cells).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a tumor with a substance, the method comprising:
 introducing a first embolization agent into a blood vessel that supplies blood to the tumor;   introducing the substance into the blood vessel after the first embolization agent has been introduced into the blood vessel, at a position that is proximal with respect to the first embolization agent; and   introducing a second embolization agent into the blood vessel after the substance has been introduced into the blood vessel, at a position that is proximal with respect to at least a portion of the substance,   wherein the first embolization agent operates to block outflow and prevent complete systemic release of the substance, and   wherein the second embolization agent operates to block inflow and prevent retrograde washout of the substance.   
     
     
         2 . The method of  claim 1 , wherein the first embolization agent comprises first embolic beads, the second embolization agent comprises second embolic beads, and the second embolic beads are larger than the first embolic beads. 
     
     
         3 . The method of  claim 2 , wherein the first embolic beads have diameters less than or equal to 100 μm, and wherein the second embolic beads have diameters greater than or equal to 200 μm. 
     
     
         4 . The method of  claim 1 , wherein the introducing of the first embolization agent into the blood vessel is accomplished by inflating a balloon to block the blood vessel and introducing the first embolization agent at a position that is distal with respect to the inflated balloon. 
     
     
         5 . The method of  claim 1 , wherein the introducing of the substance into the blood vessel is accomplished at a pressure that is sufficient to overcome a region of high pressure in a vicinity of the tumor. 
     
     
         6 . The method of  claim 1 , wherein the introducing of the substance into the blood vessel is accomplished at a pressure between 10 and 200 mmHg relative to the local pressure. 
     
     
         7 . The method of  claim 1 , wherein the introducing of the substance into the blood vessel is controlled to maintain laminar flow and to prevent non target and systemic release of the sub stance. 
     
     
         8 . The method of  claim 1 , wherein the substance comprises an immunotherapy sub stance. 
     
     
         9 . The method of  claim 1 , wherein the substance comprises CAR T-cells. 
     
     
         10 . A method of treating a tumor with a substance, the method comprising:
 introducing a catheter into a blood vessel that supplies blood to the tumor;   inflating a balloon to block the blood vessel;   introducing the substance into the blood vessel at a position that is distal with respect to the inflated balloon at a pressure that is sufficient to overcome a region of high pressure in a vicinity of the tumor; and   introducing an embolization agent into the blood vessel after the substance has been introduced into the blood vessel, at a position that is proximal with respect to at least a portion of the substance,   wherein the embolization agent acts to prevent retrograde washout of the substance and impede systemic release by impeding the forward flow of blood.   
     
     
         11 . The method of  claim 10 , wherein the embolization agent comprises embolic beads with diameters greater than or equal to 200 μm. 
     
     
         12 . The method of  claim 10 , wherein the introducing of the substance into the blood vessel is accomplished at a pressure between 10 and 200 mmHg relative to the local pressure. 
     
     
         13 . The method of  claim 10 , wherein the introducing of the substance into the blood vessel is controlled to maintain laminar flow and to prevent non target and systemic release of the substance. 
     
     
         14 . The method of  claim 10 , wherein the substance comprises an immunotherapy sub stance. 
     
     
         15 . The method of  claim 10 , wherein the substance comprises CAR T-cells. 
     
     
         16 . A method of treating a tumor with a substance, the method comprising:
 introducing a catheter into a blood vessel that supplies blood to the tumor;   inflating a balloon to block the blood vessel; and   introducing a liquid in which a plurality of substance-eluting beads are suspended into the blood vessel at a position that is distal with respect to the inflated balloon at a pressure that is sufficient to overcome a region of high pressure in a vicinity of the tumor.   
     
     
         17 . The method of  claim 16 , wherein the introducing of the liquid into the blood vessel is accomplished at a pressure between 10 and 200 mmHg relative to the local pressure. 
     
     
         18 . The method of  claim 16 , wherein the introducing of the liquid into the blood vessel is controlled to maintain laminar flow and to prevent non target and systemic release of the sub stance. 
     
     
         19 . The method of  claim 16 , wherein the substance-eluting beads comprise an immunotherapy substance. 
     
     
         20 . The method of  claim 16 , wherein the substance-eluting beads comprise CAR T-cells. 
     
     
         21 . The method of  claim 16 , wherein the substance-eluting beads primarily comprise agarose.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.